BrUOG-Brain-223-A Phase II Study of PPX (CT-2103), Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumours (CTI CT2103).

Trial Profile

BrUOG-Brain-223-A Phase II Study of PPX (CT-2103), Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumours (CTI CT2103).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2014

At a glance

  • Drugs Paclitaxel poliglumex (Primary) ; Temozolomide
  • Indications Anaplastic astrocytoma; Brain cancer; Glioblastoma; Oligodendroglioma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Oct 2012 Paclitaxel poliglumex has been granted Orphan Drug designation by the US FDA based on results of this trial, according to a Cell Therapeutics media release.
    • 24 Jul 2012 Additional lead trial centre added as reported by ClinicalTrials.gov.
    • 24 Jul 2012 Actual end date (1 Jul 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top